Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | GRK2 | P25098 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5840403 | 1.00 | TACR1 (0.42) | TACR1CCR5GRK2KDM1AMAOB | |
| SCHEMBL5840392 | 1.00 | TACR1 (0.42) | TACR1CCR5GRK2KDM1AMAOB | |
| SCHEMBL4004388 | 0.90 | TACR1 (0.48) | TACR1CYP3A4TP53CYP1A2CYP2C9 | |
| SCHEMBL4964604 | 0.90 | TACR1 (0.48) | TACR1CYP3A4TP53CYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL4006814 | 0.89 | TACR1 (0.48) | TACR1LMNACYP3A4TP53CYP1A2 | |
| SCHEMBL14498487 | 0.86 | CCR5 (0.47) | TACR1CCR5KDM1AMAOBMAOA | |
| SCHEMBL5839269 | 0.84 | TACR1 (0.47) | TACR1CCR5CACNA1FCACNA1DCACNA1S | |
| SCHEMBL4008871 | 0.84 | TACR1 (0.42) | TACR1CCR5KDM1AMAOBREN | |
| SCHEMBL4004315 | 0.84 | TACR1 (0.47) | TACR1CCR5CACNA1FCACNA1DCACNA1S | |
| SCHEMBL4007681 | 0.84 | TACR1 (0.42) | TACR1CCR5KDM1AMAOBREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957450-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-20 | — | — | EP | claimed |
| WO-2007063009-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | claimed |
| US-20070129419-A1 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. | 2007-06-07 | — | — | US | claimed |
| US-7138423-B2 | Diseases mediated by tachykinins and for seritonin reuptake transporter protein as reuptake inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060020011-A1 | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists | BRISTOL-MEYERS SQUIBB COMPANY | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129419-A1 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | SLC6A4, SLC6A2, SLC6A3 | TACR1 171/4885CCR5 1483/4885GRK2 1263/4885 |
| US-20060020011-A1 | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists | TPH1, SLC6A4, HTR1D | TACR1 24/4885CCR5 870/4885GRK2 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.